Slower than expected government orders for AIDS drugs and unreliable water supplies has knocked production at pharmaceutical manufacturer Adcock Ingram’s local factories, amplifying the effect of weak consumer demand and rising costs that saw the company deliver a mere 1% increase in headline earnings. 

Revenue rose 1% to R3.63bn in the six months to end-December 2019, compared to R3.59bn in the corresponding period the year before, while operating profit increased at the same rate (1%) to R462m, up from R457m the year before...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.